Haematology
Nuwiq
Nuwiq® is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). It is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] used to treat Hemophilia A. NUWIQ is not indicated for the treatment of von Willebrand Disease.
Fast and Accurate Control
Nuwiq® contains human coagulation factor VIII with no animal or human derived materials added during the manufacturing process or to the final medicinal product. It is a convenient twice-weekly dosing to effectively prevent bleeds in patients on personalised prophylaxis.
References
-
Nuwiq® full Prescribing Information
-
Casademunt E, et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol. 2012;89:165-176.
-
Winge S, et al. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line. Protein Expr Purif. 2015;115:165-175.
-
Sandberg H, et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res. 2012;130:808-817.
-
Kannicht C, et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res. 2013;131:78-88.
-
Valentino LA, et al. The first recombinant FVIII produced in human cells – an update on its clinical development programme. Haemophilia. 2014; 20 (Suppl. 1), 1-9.
-
Kessler C, et al. Spotlight on the human factor: building a foundation for the future of haemophilia A management. Haemophilia. 2015;21(Suppl. 1): 1–12.
-
Data on file. Hoboken, NJ: Octapharma USA, Inc; 2015.
Key Features & Benefits
-
The First and Only Recombinant FVIII Produced in Human Cells Without Chemical Modification or Protein Fusion -
Produced in human cells, not hamster cells -
B-domain deleted, no chemical modification or protein fusion -
High binding affinity to VWF (99% bound) -
Minimizing unbound FVIII may reduce risk of inhibitor development -
All Patients Experienced Fewer Bleeds with Nuwiq® Prophylaxis vs On-Demand Treatment with Another FVIII Product